Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Liquidia Corporation - Common Stock (NQ:LQDA)

14.88 -0.12 (-0.80%)
Streaming Delayed Price Updated: 10:41 AM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Liquidia Corporation - Common Stock

< Previous 1 2 3 Next >
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference
From Liquidia Technologies, Inc.
Via GlobeNewswire
U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
From Liquidia Technologies, Inc.
Via GlobeNewswire
Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference
From Liquidia Corporation
Via GlobeNewswire
District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025
From Liquidia Corporation
Via GlobeNewswire
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder
FDA sets PDUFA goal date of May 24, 2025 
From Liquidia Corporation
Via GlobeNewswire
Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025
From Liquidia Corporation
Via GlobeNewswire
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Liquidia Corporation
Via GlobeNewswire
Liquidia to Present at the Stifel 2024 Healthcare Conference
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024
From Liquidia Corporation
Via GlobeNewswire
United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent
From Liquidia Corporation
Via GlobeNewswire
Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)
From Liquidia Corporation
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting
From Liquidia Corporation
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Court Finds United Therapeutics’ Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million
From Liquidia Corporation
Via GlobeNewswire
Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement
From Liquidia Corporation
Via GlobeNewswire
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Against Liquidia Technologies, Inc. (LQDA) and Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Liquidia to Present at Upcoming Investor Conferences
From Liquidia Corporation
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.